Boston Scientific Corporation has announced significant advancements in the use of artificial intelligence $(AI)$ to predict and prevent cardiac emergencies. Their AI technology is transforming healthcare by shifting from reactive to proactive and predictive medicine, enhancing the quality of care through early diagnoses and intervention. The company's HeartLogic™ Heart Failure Diagnostic, the first FDA-approved predictive analytic alert in an implantable device, is helping identify patients at risk for worsening heart failure weeks before symptoms appear. This innovative technology analyzes various physiological biomarkers, enabling the prediction of up to 70% of heart failure cases approximately 34 days in advance, thereby allowing physicians valuable time to intervene and potentially prevent emergencies.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。